Collaboration brings MyChoice CDx Plus Testing to Hamburg, Germany and Dijon, France
Latest expansions represent Myriad’s commitment to growing international lab partner program
Myriad Genetics, Inc., a leader in genetic testing and precision medicine, has announced two new partnerships with renowned medical institutions in Hamburg, Germany and Dijon, France. These collaborations will bring MyChoice CDx Plus Testing to patients in these regions, providing them with access to advanced genetic testing services.
The partnership with the Institut für Hämopathologie in Hamburg demonstrates Myriad’s dedication to expanding its international lab partner program. By working with leading institutions around the world, Myriad is able to reach more patients and provide them with the latest advancements in genetic testing.
Similarly, the collaboration with the Centre Georges-Francois Leclerc in Dijon will bring MyChoice CDx Plus Testing to patients in France. This partnership will help to improve patient outcomes and ensure that individuals have access to personalized treatment options based on their genetic profile.
Impact on individuals:
For individuals in Hamburg and Dijon, this collaboration means that they will have access to advanced genetic testing services that can help guide their treatment decisions. By using MyChoice CDx Plus Testing, patients will be able to receive personalized treatment options based on their genetic makeup, leading to more effective and targeted care.
Impact on the world:
By expanding its international lab partner program, Myriad is taking a step towards improving global access to precision medicine. These collaborations will help to advance the field of genetic testing and bring innovative solutions to patients around the world. As more institutions join Myriad’s partner program, the reach of personalized healthcare will continue to grow, benefiting individuals and healthcare systems worldwide.
Conclusion
The partnerships with the Institut für Hämopathologie Hamburg and Centre Georges-Francois Leclerc in France mark an important milestone for Myriad Genetics and the field of precision medicine. By bringing MyChoice CDx Plus Testing to Hamburg, Germany and Dijon, France, Myriad is expanding access to advanced genetic testing services and personalized treatment options. These collaborations represent Myriad’s commitment to improving patient outcomes and growing its international lab partner program to reach more individuals around the world.
